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Abstract 
Background: Bone marrow mesenchymal stem cell (BMSCs)‑based therapy seems to be a promising treatment for 
acute lung injury, but the therapeutic effects of BMSCs transplantation on acute lung injury induced by brain ischemia 
and the mechanisms have not been totally elucidated. This study explores the effects of transplantation of BMSCs on 
acute lung injury induced by focal cerebral ischemia and investigates the underlying mechanism.
Methods: Acute lung injury model was induced by middle cerebral artery occlusion (MCAO). BMSCs (with concen‑
tration of 1 × 106/ml) were transplanted into host through tail vein 1 day after MCAO. Then, the survival, prolifera‑
tion and migration of BMSCs in lung were observed at 4 days after transplantation, and histology observation and 
lung function were assessed for 7 days. Meanwhile, in situ hybridization (ISH), qRT‑PCR and western blotting were 
employed to detect the expression of TNF‑α in lung.
Results: Neurobehavioral deficits and acute lung injury could be seen in brain ischemia rats. Implanted BMSCs could 
survive in the lung, and relieve pulmonary edema, improve lung function, as well as down regulate TNF‑α expression.
Conclusions: The grafted BMSCs can survive and migrate widespread in lung and ameliorate lung injury induced by 
focal cerebral ischemia in the MCAO rat models. The underlying molecular mechanism, at least partially, is related to 
the suppression of TNF‑α.
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Background
Over the past decades in the United States, the relative 
rate of stroke death has fallen and the actual number of 
stroke deaths has declined from the third to the fourth 
leading cause of death in population suffered stroke [1]. 
However, in low- and middle- income countries, the 
incidence and mortality of stroke were still dispropor-
tionately high [2], in which, about 95,000 people still 
experience new or recurrent stroke (ischemic or hemor-
rhagic). After stroke, several complications are still great 
challenges to physicians. Among them, not only is the 
presence of pulmonary dysfunction after stroke well rec-
ognized, but also brain lung crosstalk as a complex inter-
action, has been recognized [3–7]. Severe pulmonary 
injuries occurred not only in stroke condition, but also 
induced in brain injuries, such as severe traumatic brain 
injury (TBI) or subarachnoid hemorrhage (SAH) [8–11]. 
As pulmonary dysfunction, such as pulmonary edema 
(NPE) [6, 12], pneumonia [7], acute lung injury and the 
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severe and often result in the increase of mortality, or 
lead to the poor neurological outcome and longer inten-
sive care unit (ICU) and longer length of hospital stay 
after stroke [8, 9, 13]. Therefore, it is very important to 
find the effective method for the treatment of lung injury, 
and investigate the molecular mechanism for find the 
intervention strategy.
Currently, the pathophysiology of lung dysfunction 
after stroke is still in debate, with several theories pro-
posed. Theodore and Robin et al. first defined the “blast 
theory” of neurogenic pulmonary edema (NPE). In the 
blast theory, transient increase of intravascular pres-
sure, caused by an acute increase in intracranial pressure 
(ICP), damages the capillary-alveolar membranes which 
may cause a leak of protein-rich plasma [14]. However, 
continuous hemodynamic monitoring indicated that NPE 
may be irrelevant with hemodynamic instability [15, 16]. 
Some researchers proposed that NPE may be resulted, 
in part, from select pulmonary venoconstriction after 
massive sympathetic discharge following brain injury. 
Videlicet, pulmonary venues may be α- and β-adrenergic 
hypersensitive after brain injury. This could increase ICP 
and pulmonary pressures, and then induce direct myo-
cyte injuries with wall motion abnormalities [17]. These 
suggested that vasomotor centers by autonomic nerv-
ous system were over-estimated, which could to be an 
explanation to the association of the edema with central 
nervous system [18]. However, it could not explain the 
presence of red blood cells and protein in the alveolar 
fluid [19, 20]. In 2009, Mascia et  al. [21] described the 
“double hit” model, in which, they observed that systemic 
inflammatory reaction could induce alteration in blood–
brain barrier permeability and promote infiltration of 
activated neutrophils and macrophages to lung, thus 
cause direct damage to lung. Cascade of inflammatory 
response can cause extravasation of intravascular fluid 
and the damage of blood vessel walls, which can cause 
intra-alveolar hemorrhage [21, 22]. These observations 
suggested that a new therapeutic intervention for lung 
dysfunction is necessary after stroke.
Bone marrow mesenchymal stem cell (BMSCs), as mul-
tiple differentiation progenitor cells, are noted to be able 
to influence native immunomodulatory function [23], 
suppress local inflammatory response [24] and attenu-
ate sepsis by means of maintaining the normal pulmo-
nary endothelial, establishing epithelial interactions and 
promoting epithelial function [25, 26]. Therefore, it may 
be considered as a potential strategy for the treatment of 
lung injury, and the underlying mechanism needs to be 
investigated.
In this study, we firstly explored whether BMSCs trans-
plantation could alleviate inflammatory activities and 
improve functional consequence in lung injury induced 
by brain ischemia, then investigated the possible molecu-
lar mechanism involving in the expression of TNF-α.
Methods
Animal and grouping
Forty-five adult male Sprague–Dawley (SD) rats (weigh-
ing 180–220  g) were provided by the Center of Experi-
mental Animals, Sichuan University. All animal care, 
breeding, and testing procedures conform to the prin-
ciple of Guidance Suggestions for the Care and Use of 
Laboratory Animals promulgated by Ministry of Sci-
ence and Technology of the People’s Republic of China 
in 2006, and was approved by the Animal Care and Use 
Committee, Sichuan, University, Chengdu, China. All 
animals were housed in individual cages in a room with 
a temperature of 21–25  °C and a humidity of 45–50  % 
with a 12 h light/dark cycle and ad libitum access to pel-
let chow and water. Three groups, 15 rats in each group, 
were randomly designated as sham group, brain ischemia 
group (BI) and BMSCs transplantation group (BMSCs), 
as shown in Fig. 1.
Induction of focal cerebral ischemia
Permanent focal cerebral infarction was introduced by 
bipolar coagulation of the left middle cerebral artery 
(MCA) as described previously [10]. After 3.6 % chloral 
hydrate (1 ml/100 g) intraperitoneally injection, left com-
mon, internal and external carotid arteries were exposed 
through a midline neck incision and were carefully 
Fig. 1 Experiment design for transplantation of BMSCs in rat with 
brain ischemia‑induced pulmonary injury. mNSS modified neurologi‑
cal severity score for measuring neural function after brain ischemia. 
TTC staining 2, 3, 5‑Triphenyltetrazolium chloride for measuring the 
viability of brain tissue. ICC immunocytochemistry staining to identify 
the BMSCs. qRT-PCR quantitative real‑time polymerase chain reaction 
for detecting the mRNA expression of TNF‑α. HE staining hematox‑
ylin‑eosin staining. W/D ratio wet‑to‑dry weight ratio of lung. WB 
western blot analysis for quantifying the protein level of TNF‑α. IHS 
immunohistochemistry staining for analyzing the expression of TNFα. 
ISH in situ hybridization for determining the location of TNF‑α in lung 
with cerebral ischemia. BI brain ischemia. BMSCs brain ischemia with 
BMSCs transplantation
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dissected from the surrounding tissues with help of 
an operating microscope. After electrocoagulation of 
the external and common carotid arteries, a 3-0 silicon 
rubber-coated monofilament (Shadong Biotech, Bei-
jing, China) was inserted through the common carotid 
artery into the internal carotid artery 18–20 mm beyond 
the carotid bifurcation to the base of the middle cerebral 
artery, while 10 mm for sham group. The pterygopalatine 
branch of the internal carotid artery was exposed before 
the insertion in order to avoid the filament turning into 
it. Rectal temperature was maintained at 36.5–37  °C 
using a heat lamp during the operation and for 2 h after 
MCAO, and breath and heart rate were monitored all the 
time.
Assessment of neurological function
Each rat was subjected to a series of behavioral tests by 
using modified neurological severity score (mNSS) [27] 
24  h after MCAO to identify the model reliability. The 
mNSS (0–18) is determined by motor (muscle status, 
abnormal movement), sensory (visual, tactile, proprio-
ceptive), reflex, and balance tests. In the severity score 
of injury, one score point is awarded for the inability to 
perform the test or for the lack of a tested reflex; thus, the 
higher the score is, the more severe the injury is. All rats 
were given enough time to become familiar with the test-
ing environment before inflicting the brain injury. This 
test was completed by three trained and qualified observ-
ers who were blinded to the groups of animals.
Isolation of bone marrow mesenchymal stem cell (BMSCs)
BMSCs from SD rats (4  weeks, 60–80  g) were isolated 
and harvested as described previously [11]. In brief, 
bone marrow tissues were acquired from the cavities of 
femurs and tibias with a syringe and 22-gauge needle and 
injected into the culture medium (Dulbecco’s modified 
Eagle’s medium, Gibco, Carlsbad, CA, USA; 10  % fetal 
bovine serum, Hyclone, Logan, UT, USA; 2  mM  l-glu-
tamine; 10,000 U/L penicillin, and 10 mg/L streptomycin, 
Gibco BRL, Life Technologies, Paisley, United Kingdom). 
All the flushing fluid was turned into the single-cell sus-
pension and seeded into 15 ml culture flasks with culture 
medium. Cells were cultured at 37  °C in a humidified 
environment with 5  % CO2. Non adherent cells were 
removed 24  h later, and adherent cell colonies were 
washed three times with phosphate-buffered saline solu-
tion (PBS, Life Technologies). Fresh complete medium 
was added and changed every 3–4 days. Cells were sub-
cultured 1:2 or 1:4 when they reached 80–90  % conflu-
ence. Cells used in this experiment were all harvested 
from the third passage. Cell surface markers CD29, CD44 
and CD45 were detected by immunocytochemistry stain-
ing to identify BMSCs.
Immunocytochemistry staining
Monolayer and single colony-derived adherent cells (at 
the third passage in culture) were analyzed by immuno-
cytochemistry. Cytospin preparations and growing cells 
in 6-well culture plate were fixed in 4  % paraformalde-
hyde for 20  min at 4  °C, washed three times with PBS, 
and then incubated with 3 % hydrogen-peroxide (H2O2; 
Sigma-Aldrich) at room temperature for 30 min. The cells 
were permeabilized and pre-incubated with blocking 
solution (containing 2 % goat serum, 0.3 % Triton X-100, 
and 0.1 %BSA in PBS) for 30 min at room temperature, 
and then blocked with 5  % normal goat serum at room 
temperature for 30  min. Washed slides were separately 
incubated with anti-CD44 (1:50, Abcam, USA), anti-
CD29 (1:50, Abcam, USA) and anti-CD45 (1:50, Abcam, 
USA) primary antibody at 4 °C overnight. After washing 
with PBS, Alexa Fluor 488 anti-goat IgG (1:200; Molecu-
lar Probes, Carlsbad, CA, USA) was incubated for 1 h at 
37 °C. Nuclear staining was performed by treatment with 
4′, 6-diamidino-2-phenylindole (DAPI, 1:20,000; Molec-
ular Probes, Carlsbad, CA, USA) for 5  min. Slices were 
then mounted and observed with a florescent microscope 
(Leica, Solms, Germany).
BMSCs death assessments of Trypan Blue staining in vitro
Before transplantation, the cell mortality of BMSCs was 
evaluated by Trypan blue assay (Sigma-Aldrich, St. Louis, 
MO, USA). BMSCs suspension was balanced in PBS. 
500  µL of 0.4  % Trypan Blue solution (w/v) was trans-
ferred to a test tube. Then 300  µL of PBS and 200  µL 
BMSCs suspension (dilution factor = 5) were added and 
mix thoroughly. Cells were counted using a countess 
automated cell counter (Invitrogen Life Technologies, 
Grand Island, NY Life Technologies, Grand Island, NY, 
USA) after 3 min staining at room temperature. The dead 
cells were stained with blue color. Count cells on top and 
left touching middle line of the perimeter of each square. 
And cells touching the middle line at bottom and right 
sides were not count. Cell inhibitory ratio was calculated 
by the following formula: cell mortality (%) =  (the dead 
cell number/the total number) × 100 %.
BMSCs transplantation procedures
BMSCs from SD rats were prepared and transplanted into 
SD rats. Two days before and after BMSCs transplantation, 
SD rats were injected Cyclosporin A (10 mg/kg) for three 
consecutive days. To trace the BMSCs after transplantation, 
they were labeled with Hoechst33342 with a final concen-
tration of 10  μM in the culture medium and were incu-
bated for 2 h. BMSCs were washed three times with PBS to 
remove unbound Hoechst dye, digested with 0.25 % (w/v) 
trypsin (Gibco), and then suspended in complete medium. 
After centrifuged and washed with PBS for several times, 
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cells were suspended in a serum-free medium at 1 ×  106 
cells per 1  ml. In BMSCs group, the rats were given an 
intravenous (through tail vein) injection of 2 ml of BMSCs 
suspension with 2  ×  106 cells for 10  min one day after 
MCAO. Penicillin (20 U/rat/day) was injected intraperito-
neally for three consecutive days after BMSCs transplan-
tation to prevent infection. The route, dose and timing of 
administration have been used in a previous study [28–30].
Tissue preparation
Animals were re-anaesthetized with 3.6 % chloral hydrate 
(1 ml/100 g). The chest cavity was opened and the hilum 
of left lung was ligatured. The right lung was perfused 
with normal saline for 10 min and then slowly fixed with 
4  % paraformaldehyde for 30  min. The brain and right 
lung were obtained and post fixed in 4  % paraformal-
dehyde (solution in 0.1 mol/L phosphate buffer, pH 7.4) 
overnight at 4  °C. The sample was then dehydrated in 
20  % sucrose solution in 4  % paraformaldehyde, and 
then with 30 % sucrose solution in 0.1 mol/L phosphate 
buffer. Subsequently, samples were embedded in paraffin 
and sectioned (5 μm in thickness). The left lung without 
fixing was harvested and stored at −80 °C for west blot-
ting. In addition, 3 days after MCAO, lung tissue was also 
harvested for qRT-PCR. Sections obtained 4  days after 
BMSCs transplantation were also employed to observe 
the distribution of Hochest33342 labeled BMSCs lung 
tissue under fluorescence microscope.
2, 3, 5‑Triphenyltetrazolium chlorides(TTC) staining 
and evaluation of infarction volume after MCAO
Viability of brain ischemia was evaluated using TTC 
(Sigma-Aldrich, St. Louis, Missouri, USA) 24  h after 
MCAO. Rat brains were rapidly removed, frozen at −80 °C 
for 5  min and then sliced coronal into serial 2-mm-thick 
slices at the level of the bregma. Sets of five serial slices 
from each brain were incubated for 30 min at 37 °C in 2 % 
TTC (Sigma Co., St Louis, MO, USA) in the dark washed 
in PBS, and then fixed by 4 % formaldehyde in PBS. Images 
of sections from the exact center of the forebrain were cap-
tured using digital camera system (Leica, Solms, Germany). 
The infarction area and hemisphere area of each section 
were traced and measured using Image Pro plus 6.0 soft-
ware (Media Cybernetics, Inc., MD, USA). To eliminate 
the interference of brain edema, the infarct volume was 
corrected by standard methods (contralateral hemisphere 
volume–volume of non-ischemic ipsilateral hemisphere). 
Infracted volume was expressed as a percentage of the con-
tralateral hemisphere, as described previously [31, 32].
Lung function assessment and edema measurement
Arterial blood gas analysis and wet-to-dry weight (W/D) 
ratio of lung were used to represent the severity of lung 
edema. Seven days after MCAO, rats were re-anaesthe-
tized with 3.6  % chloral hydrate (2  ml/100  g) intraperi-
toneally. Arterial blood samples (100  μl) of rats were 
extracted into a heparinized syringe by left ventricular 
sampling, and then blood gas analysis was immediately 
performed with blood-gas analyzer (RADUOMETER 
ABL800). In addition, after equivalent lung tissue in bilat-
eral was separated from the thoracic cavity, the lungs 
were weighed and then dried to constant weight at 80 °C 
for 24  h. The ratio of wet-to-dry was finally calculated 
using the formula of (dry weight/wet weight) × 100 %.
Hematoxylin–eosin staining and immunohistochemical 
assay
Brains and lung were removed and placed in 10 % para-
formaldehyde in phosphate-buffer overnight, dehydrated, 
and embedded in paraffin. 5  μm-thick serial sections of 
the right lung and brain were stained with hematoxylin-
eosin (HE). For immunohistochemical assay, the paraf-
fin embedded sections were routinely de-paraffinized 
and rehydrated. After non-specific antigen site blocking, 
the slices of lung tissue were incubated with monoclonal 
mouse anti-TNF-α (dilution 1:50, Abcam, Cambridge, 
UK), and then the slices were performed at room temper-
ature for 1 h and then incubated overnight at 4  °C. The 
sections were incubated in biotin-conjugated secondary 
antibody for 30  min at 37  °C and then incubated with 
horseradish peroxidase conjugated streptavidin avidin for 
20 min at 37  °C. Washing was performed with PBS (pH 
7.4) for three times (5  min for each time) between any 
two adjacent procedures, except for blocking in serum. 
Then, visualization was done with diaminobenzidine 
(DAB), followed by dehydration, transparentization and 
mounting. Counterstaining of sections by hematoxylin 
was also performed. Negative controls were stained simi-
larly. However, PBS was used, instead of a primary anti-
body. Images were taken with a laser scanning confocal 
microscope (Nikon, Tokyo, Japan). Quantification of the 
immunolabeled lung sections was performed separately. 
For each slice,  ×200 magnification photomicrographs 
were taken to measure the density of TNF-α. The mean 
density was presented as IOD over the area of interest 
using Image-Pro plus 6.0 software (Media Cybernetics, 
Silver Spring, MD, USA), which was described previously 
[18]. Data are presented as mean ± SEM. Observers were 
blinded to group identity.
In situ hybridization
Slides, prepared as described, were used for ISH. Briefly, 
sections were de-waxed in xylene, rehydrated in gradedal-
cohols, and placed in diethyl pyrocarbonate (DEPC) H2O. 
Endogenous peroxidase was inactivated by incubation 
in 3  % H2O2 for 15  min at room temperature. Sections 
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were then digested in proteinase K (20 μg/ml) for 20 min, 
rinsed in NaCl/Tris, and then fixed in 4 % PFA for 10 min. 
Following this, slides were rinsed with PBS twice for 
5  min. Slices were blocked at room temperature for 2  h 
in hybridization buffer (50 % formamide, 25 % 5× saline 
sodium citrate (SSC), 10  % 5×  Denhardt’s and 15  % 
DEPC-H2O (containing 200  ng/ml yeast RNA, 500  g/ml 
salmon sperm DNA and 20  mg/ml Roche blocking rea-
gent)), hybridized with 30  nmol of locked nucleic acid 
(LNA)-modified oligonucleotide probe (Exiqon, Woburn, 
MA, USA) complementary to TNF-α, and then labeled 
with digoxigenin (DIG) at 52 °C overnight. After hybridi-
zation, the slides were washed in 2× SSC twice at 37  °C 
for 15 min after washing with 0.5× SSC (15 min at 37 °C) 
and 0.2×  SSC (15  min at 37  °C). The slides were then 
incubated with HRP conjugated anti-DIG antibody. Sec-
tions were rinsed in PBS three times for 5 min. Peroxidase 
staining was visualized with DAB for 3 min.
Detection of BMSCs cells and phenotypic analysis in vivo
Four days after transplantation, the phenotype of BMSCs 
in  vivo was detected. Lungs of the deeply-anesthetized 
rats were removed, fixed in 4  % paraformaldehyde in 
phosphate-buffer, dehydrated with 30 % sucrose in 0.1 M 
PBS for overnight, and frozen in powdered dry ice. Cry-
ostat sections (10 μm) were processed. Phenotypic analy-
sis of the transplanted cells in vivo was carried out using 
fluorescence microscope (Leica, Solms, Germany).
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
Three and seven days after MCAO, the mRNA expres-
sions of TNF-α and β-actin in the lung were detected by 
qRT-PCR. In brief, the left upper lung tissues were kept 
at −80  °C, then the total RNA was isolated from lung 
homogenates with Trizol reagent (Takara Bio Inc., Otsu, 
Japan) and reverse transcribed using PrimerScript® RT 
reagent Kit with cDNA eraser (Takara Bio Inc., Otsu, 
Japan). Each PCR was performed with a iQ™5Multicolor 
RealTime PCR Detection System (Bio-Rad Laborato-
ries, Inc., USA) and a SYBR Green PCR kit (Takara Bio 
Inc., Otsu, Japan) in a final volume of 20 μL, containing 
1.6  μL cDNA template, forward and backward prim-
ers 0.8  μL each, 10  μL SYBR® Premix Ex Taq™II and 
6.8  μL dH2O. The primers and Taqman probes were 
designed using Primer Premier (PREMIER Biosoft 
International, Canada). The premier sequences were as 
follows: TNF-α (forward) 5′-AATGACCCAGATTAT 
GTTTGAGAC-C-3′ and (reverse) 5′-TCCAGAGTCCA 
GCACAATACCAG-3′; β-actin (forward) 5′-GATTA 
CTGCTCTGGCTCCTAGC-3′ and (reverse) 5′-ACT 
CATCGTACTCCTGCTTGCT-3′. The mouse β-actin 
housekeeping gene was used as an internal control. The 
fluorescence emitted by the reporter dye was detected in 
real time, and the threshold cycle (Ct) of each sample was 
recorded as a quantitative measure of the amount of PCR 
product in the sample. The target signal was normalized 
against the relative quantity of β-actin and expressed 
as ΔCt  =  Cttarget  −  Ctβ-actin. The changes in target sig-
nal relative to the total amount of genomic DNA were 
expressed as ΔΔCt  =  ΔCttreatment  −  ΔCtcontrol. Relative 
changes in metastasis were then calculated as 2−ΔΔCt [13].
Western blot analysis
Seven days after MCAO, the protein expression of 
TNF-α was determined by western blot. The left mid-
dle lung tissues were kept at −80  °C and homogenized 
in PBS containing the protease inhibitor cocktail with 
the aid of a tissue grinder. The homogenates were cen-
trifuged for 15  min at 12,000 rpm and 4  °C. Superna-
tants were collected, and the protein concentration of 
each sample was measured with Bradford protein assay 
kit (BioRad Laboratories, Inc., USA) using bovine serum 
albumin (BSA) as the standard. An equal amount of 
protein from each sample (25  μg) was resolved in 15  % 
SDS-polyacryamide gel (SDS-PAGE). After electropho-
resis, the separated protein bands were wet transferred 
to the polyvinylidenedifluoride (PVDF) membrane (Mil-
lipore, Bedford, MA, USA). Nonspecific binding to mem-
brane was blocked with 5 % skim milk (Sigma, USA) in 
TBST (10 mmol/L Tris, pH 8.0,150 mmol/L NaCl, 0.05 % 
Tween 20) for 1 h at room temperature. The membranes 
were incubated for 24 h at 4 °C with primary anti-TNF-α 
IgG (1:1000, Abcam, Cambridge, UK),and anti-β-actin 
antibody(1:2500, Santa Cruz Biotechnology, Inc., USA) 
respectively. The secondary antibody (horseradish perox-
idase-conjugated goat anti-mouse IgG in 5 % skim milk-
TBS-T) was added at 1:20,000 dilutions and incubated for 
2 h at room temperature. Immunodetected proteins were 
visualized using ECL assay kit (Millipore, Bedford, MA, 
USA) with glyco doc imaging system (Bio-Rad Laborato-
ries, Inc., USA) and analyzed by Quantity One software. 
The relative protein level was normalized to β-actin.
Statistic analysis
Sigma plot software SPSS version 17.0 (SPSS Inc., Chi-
cago, USA) was used to perform data analysis. All data 
were expressed as mean ± standard deviation (SD). Dif-
ferences between control and experimental group were 
compared by One-Way analysis of variance (ANOVA) 
and P < 0.05 was considered to be statistically significant.
Results
Cerebral ischemia induced acute lung injury
MCAO has a high mortality, about 60–70 %, in our study. 
After brain ischemia, the pyramidal cells in the cortex 
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were exhibited acellular edema (Fig.  2a, b). Neurologic 
function evaluation showed that mNSS score was higher 
in the brain ischemia group 24 h after MCAO, as com-
pared with the Sham group (P < 0.05) (Fig. 2c). Normal 
lung tissue structures and clear alveoli existed in rats of 
Sham group, and there are few inflammatory cells in the 
lung tissue (Fig.  2d). Comparatively, in brain ischemia 
group, many cells with nuclei were large and deep dyed 
were observed, and these cells were considered as mac-
rophages (Fig. 2e). The alveolar walls are thickened; cap-
illaries in the alveolar walls are congested with many 
red blood cells, local hemorrhage, interstitial edema, 
alveoli exudation and inflammatory cells were observed 
in lungs in brain ischemia group. Some inflammatory 
cells were passing through the vascular wall to the pul-
monary interstitial. Various pathological changes were 
observed in the same pulmonary lobe (Fig.  2e). In the 
brain ischemia group, the counts of red cells in lung 
were significant increased, as compared with the Sham 
group (Fig.  2f ). Moreover, 7  days after MCAO, wet-to-
dry weight (W/D) ratio of lung in brain ischemia group 
elevated, as compared with the Sham group (P  <  0.05, 
Fig.  2g). TTC staining showed the volume of infarct in 
the brain of MCAO is apparent as compared with Sham 
one (Fig.  2h). Ischemic infarcts include ipsilateral fron-
tal lobe, parietal lobe and the front of the temporal lobe 
after MCAO (Fig.  2h), and the average infarct percent-
age is approximately 21 %.
Fig. 2 Cerebral ischemia induced by MCAO produces lung injury in rat. a, b Morphological examination of the cerebral cortex neurons by H&E 
staining. a Sham group; b BI group. a In Sham group, there were abundant pyramidal cells. b After brain ischemia, the nuclei of pyramidal cells (bold 
arrow) were shrunken and surrounded with acidophilic cytoplasm. c mNSS score in the Sham group and BI group at 24 h after MCAO. d, e H&E 
staining of the lung tissue in Sham group (d) and BI group (e). Red blood cells (bold arrow) were observed in the pulmonary alveoli (e). f Bar graph of 
the numbers of red cells in the lung in Sham group and BI group was shown. g Wet‑to‑dry weight (W/D) ratio of lung in Sham group and BI group 
was shown. h Viability of brain tissue was shown by TTC staining in rats suffered MCAO. i Bar graph of the infarct volume percentage in Sham group 
and BI group were shown. *P < 0.05;**P < 0.01, n = 5 in each group. Scale bars a,b, d, e, 25 μm; h, 200 μm
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Analysis of lung function and TNF‑α expression after brain 
ischemia
Blood gas analysis confirmed that PaO2 decreased and 
PaCO2 increased after brain ischemia, compared with 
the Sham group(both P < 0.05, Fig. 3a, b). Either mRNA 
(Fig.  3c, d) or protein (Fig.  3e) expression of TNF-α in 
lung significantly increased after MCAO, compared with 
the Sham group (P < 0.05).
Expression and localization of TNF‑α in lung after brain 
ischemia
Immunohistochemistry showed that in Sham group, 
TNF-α staining was junior in alveolar type I and 
type II epithelial cell, and few macrophagocytes was 
stained by TNF-α recognition (Fig. 4a). While in brain 
ischemia group, intensity of staining in typeIand II 
epithelial cells were both increased, a stronger dyeing 
of TNF-α was observed in alveolar type I and type II 
epithelial cells (Fig.  4b). What’s more important, more 
macrophagocytes with TNF-α strong positive staining 
were observed in lung after MCAO (Fig. 4b). ISH indi-
cated that TNF-α was mainly located in macrophago-
cytes, which were significantly increased in the brain 
ischemia group (Fig. 4c, d).
Morphological and surface antigen characteristics 
of primary BMSCs
Primary BMSCs cultured as plastic adherent cells. They 
turned to confluency one week after culture and were 
expanded by serial subcultivation just prior to confluency. 
Figure 5a showed the morphological features of BMSCs 
at 0 h. At the 3rd day, their clonal-rosette derived round 
shape became elongated or spindle-shaped (Fig.  5b). 
At the 3rd passage, the form of primary BMSCs adher-
ent cells was uniform with polygons-shaped appearance 
(Fig.  5c). To characterize primary BMSCs phenotype, 
we examined the cell surface markers CD29, CD44, and 
CD45 by means of immunocytochemistry staining. The 
Fig. 3 Lung function was deteriorated and the expression of TNF‑α in lung was increased after MCAO. a, b Blood gas analysis of the Sham group 
and BI group. PaO2 (a); PaCO2 (b). c, d qRT‑PCR assessment of the mRNA expression of TNF‑α in the Sham group and BI group at 3(c) and 7(d) days 
after MCAO. e Western blot assessment of the protein expression of TNF‑α in lung tissues in the Sham group and BI group. A semi‑quantitative 
analysis was used to represent the total protein level of TNF‑α. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 compared to the Sham group, 
n = 5 in each group
Page 8 of 14He et al. Behav Brain Funct  (2016) 12:9 
BMSCs were positive for CD29 (Fig.  5d–f) and CD44 
(Fig.  5g–i), but negative for CD45 (Fig.  5j–l). This indi-
cates that the cells were highly expressed markers of mes-
enchymal stem cells and were negative for endothelial 
and hematopoietic cell markers.
BMSCs engrafts improved lung morphology and alleviated 
TNF‑α expression
Trypan Blue staining indicated that the viability of 
BMSCs is about 96  %, before transplantation. Brain 
ischemia induced prominent lesions in lung and 
increased the inflammatory exudations in alveolar and 
inflammatory cells (Fig. 6a, c). In contrast, inflammatory 
exudations in alveolar and inflammatory cells were partly 
ameliorated by BMSCs treatment (Fig. 6b, d). Within the 
lung tissue, the transplanted BMSCs could be easily iden-
tified under fluorescent microscopy, and their nucleic 
appearances were exactly the same as that before the 
transplantation (Fig. 6e). Cells derived from BMSCs were 
round-to-oval with irregular dark brown nuclei and thin 
cytoplasm by Hoechst33342 staining (Fig. 6e). Moreover, 
both the mean density of TNF-α (Fig. 6f ) and the num-
ber of the inflammation cells (Fig. 6g) were significantly 
decreased in BMSCs transplantation group (vs brain 
ischemia group, P < 0.05).
Analysis of lung function and TNF‑α expression 
after treatment of BMSCs in brain ischemia rats
Seven days after BMSC transplantation, wet-to-dry 
weight(W/D) ratio of lung in BMSCs group decreased, 
as compared with rats subjected to only brain ischemia 
(P  <  0.05, Fig.  7a). Blood gas analysis indicated that 
PaO2 increased (P < 0.05, Fig. 7b) and PaCO2 decreased 
(P < 0.05) (Fig. 7c) after BMSCs treatment, as compared 
with the brain ischemia group. Furthermore, there was 
a significantly decrease in the level of TNF-α (Fig. 7d, e) 
mRNA or protein expression (Fig. 7f ) both 3 and 7 days 
after BMSCs transplantation, as compared with the brain 
ischemia group (both P < 0.05).
Discussion
The major findings of these experiments can be sum-
marized as follows: (1) brain ischemia could induce lung 
injury, a kind of inflammatory lung damage; (2) intra-
venous injection of BMSCs could home to the lung and 
survive in brain ischemia induced lung injury model; (3) 
Fig. 4 Representative histopathological finding of TNF‑α in the injured lung after brain ischemia. a, b Immunohistochemistry staining of TNF‑α in 
type I (brown signal, bold arrow), II lung epithelial cells (brown signal, thin arrow) and macrophagocytes (brown signal, arrow head) in the Sham group 
(a) and BI group (b). c, d ISH of TNF‑α (red signals) was detected in the typeI (ISH, red signals, bold arrow), II lung epithelial cells (ISH, red signals, thin 
arrow) and macrophagocytes (ISH, red signals, arrow head) in the Sham group (c) and BI group (d). Scale bars a–d, 25 μm
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treatment with BMSCs could reduce pulmonary edema, 
improve lung function after brain ischemia; (4) BMSCs 
exhibited a positive role in suppressing inflammation 
mediators like TNF-α in lung after brain ischemia.
In this study, we found that permanent MCAO induced 
pulmonary injury in SD rats. Pulmonary dysfunction 
is an important independent factor that affects mortal-
ity in patients suffering brain injury and deteriorates the 
long-term neurologic outcome [13, 32–34]. Ségolène 
Mrozek et  al. suggested that brain lung crosstalk is a 
complex interaction from the brain to the lung but also 
from the lung to the brain. Several studies described the 
occurrence of severe pulmonary injuries after experienc-
ing a brain injury, such as severe traumatic brain injury, 
subarachnoid hemorrhage, stroke or hypoxic-ischemic 
brain damage [8, 10, 33–35]. The pathophysiology of 
brain-lung interaction is complex and several hypotheses 
have been proposed with a particular described “double 
hit” model [21]. After brain ischemia, there was local 
hemorrhage, interstitial edema, alveoli exudation and 
Fig. 5 Isolation and identification of BMSCs. a, b, c Cellular morphology of BMSCs at 0 h (a) 3‑day (b) and the 3rd passage (c) in primary culture 
which were observed under inverted phase contrast microscope CD29, CD44 and CD45 immunostaining of the 3rd passage of BMSCs were per‑
formed. Immunostaining of CD29 (d, red), CD44 (g, red) and CD45 (j) with nucleus stained DAPI (e, h, k respectively, blue) and the merge graphs  
(f, i, l) were showed. Scale bars a, b, c, 100 μm; d–l, 25 μm
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inflammatory infiltrates in lung. This injury presents as a 
kind of inflammatory lung damage characterized by his-
tology study and increased tissue TNF-α concentration 
in the lung.
Intravenous injection of BMSCs could home to the 
lung and survive after brain ischemia. The ability to self-
renew and multi-directional differentiation make BMSCs 
attractive as a potential treatment for acute lung injury. 
Four days after BMSCs treatment, migration towards 
and adhesion of BMSCs with Hochest33342 labeled 
were observed in the rat lung tissue under fluorescence 
microscope Muhammad Aslam et  al. [23] did observe 
that a higher number of donor BMSCs can be detected 
in the injured lung compared with the normal lung at 
10  days post injection. This elucidated that the intra-
venous transplanted BMSCs could partially maintain 
themselves in the injured lung. Although we cannot 
propose that BMSCs extensively replace injured lung 
cells to effectively improve lung architecture because of 
the minimal BMSC engraftment after transplantation, 
this may be the basis for functional and morphological 
improvement [23, 36].
Fig. 6 BMSCs transplantation decreased the expression of TNF‑α and the numbers of inflammatory cells in lungs of rats after MCAO. a, b The intra‑
cellular TNF‑α in lung (brown signal, thin arrow) was detected by immunohistochemistry. The photos represented the intracellular TNF‑α content of 
lung in BI group (a) and BMSCs group (b). c, d Inflammatory cells in lung of rats in BI group (c) and BMSCs group (d) were detected by HE staining. 
e Hochest33342 labeled cells (blue) in lung under fluorescence microscope. f Bar graph of mean density of TNF‑α in the lung in BI group and BMSCs 
group. g Numbers of inflammatory cells were calculated in BI group and BMSCs group. (*P < 0.05, n = 5 in each group). a–d, 25 μm; e, 100 μm
Page 11 of 14He et al. Behav Brain Funct  (2016) 12:9 
In the present study, we have shown that BMSCs 
enhance the recovery of lung structure and function 
after brain ischemia. Specifically, BMSCs treatment 
improved lung architecture, restored static lung compli-
ance, and ameliorate alveolar fluid exudation in lung, as 
evidenced by reduced lung wet- to- dry weight ratio, his-
tological evidence of reduced alveolar tissue edema and 
the improved blood gas analysis. These findings support 
previous findings that BMSCs normalize lung fluid bal-
ance and alveolar fluid clearance through therapeutic 
effects on the lung endothelium [37]. The integrity of the 
lung microvascular endothelium is essential to prevent 
the influx of protein-rich fluid from the plasma as well as 
inflammatory cells which may further aggravate the abil-
ity of the lung epithelium to remove alveolar edema.
BMSCs suppress inflammation responses in lung 
after brain ischemia. BMSCs were demonstrated by 
prior studies to have anti-inflammatory effects on lung 
injury. Gupta et  al. [11] found that intrapulmonary 
delivery of BMSCs in mice mediated a down-regulation 
of pro-inflammatory responses to endotoxin by reduc-
ing TNF-α and macrophage inflammatory protein-2, 
while increasing the anti-inflammatory cytokine IL-10. 
BMSCs therapy can attenuate paraquat-induced ALI in 
rats through decreases plasma TNF-α and MDA levels. 
BMSCs have demonstrated benefit in oleic acid induced 
acute lung injury in rats by decreased TNF-α expres-
sion and increased IL-10 content [38]. BMSCs decreased 
lung inflammation ventilator-induced lung injury rat, by 
reduced TNF-α and upregulated IL-10 [39].
In our study, we found a significantly increase of TNF-α 
concentration in the lung tissue after brain ischemia. 
Inflammatory cytokines may key mediator for pulmonary 
alveoli injury. TNF-α could distract vascular endothe-
lial cells, leading to the increase of capillary permeabil-
ity and the development of lung inflammation response 
[40]. TNF-α induced NF-κB signaling activation in whole 
lung has been proven to be associated with inflammation 
damage in pulmonary complication [41, 42].
On the other hand, it’s generally accepted that the ben-
eficial effects of stem and progenitor cells in animal dis-
ease models are the result of immunomodulatory and 
trophic support properties delivered by the transplanted 
cells acting in a paracrine manner. BMSCs might produce 
Fig. 7 BMSCs ameliorated lung function and reduced the expression of TNF‑α in lung after MCAO. a Wet‑to‑dry weight (W/D) ratio of lung in BI 
group and BMSCs group. b, c Blood gas analysis of the BI group and BMSCs group. PaO2 (b); PaCO2 (c). d, e mRNA expression of TNF‑α in BI group 
and BMSCs group at 3 (d) and 7 (e) days after MCAO. f Western blot assessment of the protein expression of TNF‑α in lung tissues in BI group 
and BMSCs group 7 days after MCAO. Semi‑quantitative analysis was used to represent the total protein level of TNF‑α. Data are expressed as 
mean ± S.D. *P < 0.05, **P < 0.01 compared to the BI group, n = 5 in each group
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a number of potent cytokines and growth factors, such as 
platelet-derived growth factor (PDGF) and transforming 
growth factor β (TGF-β1) to repair the process of lung 
injury [43, 44].
We performed the cell transplantation at 24  h after 
stroke, which needs to be justified. It was reported 
that BMSC transplantation acutely after stroke was 
deteriorating to the ischemic brain. The high level of 
VEGF in these cells may cause brain edema. How-
ever, the relationship between VEGF and brain edema 
has been debated, also. Some literatures demonstrated 
that the up-regulated VEGF after ischemic stroke may 
significantly increase the brain water content [45–47] 
and induce vasogenic brain edema [48, 49]. VEGF has 
the potency to increase vascular permeability [50, 51]. 
After brain ischemia, VEGF could significantly increase 
BBB leakage [52]. VEGF disrupts the organization of 
interendothelial junctions (IEJ) and the integrin-extra-
cellular matrix (ECM) complexes, thereby opening 
the junctional barrier. Nicholas van Bruggen et al. [53] 
established that sequesters murine VEGF could signifi-
cantly reduce the acute appearance of cortical edema 
after focal cerebral ischemia [53]. However, the role of 
VEGF in the pathogenesis of the formation of ischemic 
brain edema is unclear with contradictory experimen-
tal observations. For example, Hayashi et  al. reported 
that VEGF itself, when applied topically to the surface 
of a reperfused rat brain after transient cerebral artery 
occlusion, reduced ischemic brain damage, infarct vol-
ume, and edema formation. Harrigan MR et  al. [54] 
demonstrated that intracerebroventricular infusion 
of VEGF decreases infarct volume and brain edema 
after temporary MCAO. Betz et  al. [55] suggested that 
ischemic brain edema formation in the relatively early 
phase is mainly caused by cytotoxic edema rather than 
vasogenic edema [56]. On the other hand, VEGF may 
protect the blood–brain barrier rather than destroy it 
after brain ischemia because Criscuolo et al. suggested 
that VEGF application through the carotid artery did 
not cause albumin extravasation. The amelioration of 
blood–brain barrier injury may be attributable to the 
protective effect of VEGF on endothelial cells [57]. 
One possible mechanism of VEGF in the reduction of 
ischemic brain edema is that VEGF could reduce the 
infarct volume by protection of endothelial cells, and 
thus reduce water content, without exacerbating vaso-
genic edema. Chen Bo et  al. [54] suggested that VEGF 
gene modified BMSCs adenovirus could reduce reac-
tive gliosis, ameliorate neurological deficit, diminish the 
percentage of cerebral infarction volume in rats, and 
facilitate angiogenesis [58]. In addition, BMSCs trans-
plantation could ameliorate neurological deficit and 
increase neurogenesis as the result of VEGF-mediated 
angiogenesis without brain ischemia [59]. Therefore, 
it seems that BMSCs combined with VEGF may play a 
more significant role in protecting brain ischemia.
Together, our results give vital evidences that BMSCs 
treatment may be a potential effective therapy for pul-
monary complication after brain ischemia derived brain 
ischemia. Moreover, BMSCs may regulate TNF-α expres-
sion in brain ischemia induced lung injury. Therefore, 
BMSCs treatment can reduce lung injury, in which, the 
possible mechanism may link to the inhibition of TNF-α 
in brain ischemia induced lung injured rats. Our findings 
is first time to show the protective effects of BMSCs in 
brain ischemia induced lung injury, which is linked to the 
inhibition of TNF-α expression.
Conclusions
We concluded that the intravenous transplantation of 
BMSCs originated from the bone marrow could par-
tially ameliorate lung injury induced by brain ischemia, 
and inhibited the mobilization of inflammatory cells and 
reduce the TNF-α protein expression in lung. The pre-
sent data indicate that BMSCs may serve as the basis of 
a novel therapeutic approach for patients suffering from 
pulmonary complications after brain injury, based on the 
TNF-α inhibition, in future clinic practice.
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